A Randomised Comparison of Daily 25 mg Versus 5 mg Lenalidomide as Maintenance Therapy After High-Dose Therapy and Autologous Stem Cell Transplantation in Patients With Multiple Myeloma.
Phase of Trial: Phase III
Latest Information Update: 04 Jul 2017
At a glance
- Drugs Lenalidomide (Primary)
- Indications Multiple myeloma
- Focus Registrational; Therapeutic Use
- Acronyms LenaMain
- 17 Feb 2017 Status changed from active, no longer recruiting to completed.
- 19 Aug 2015 Planned End Date changed from 1 Jun 2018 to 1 Dec 2016 as per ClinicalTrials.gov record.
- 19 Aug 2015 Planned primary completion date changed from 1 Jun 2018 to 1 Dec 2016 as per ClinicalTrials.gov record.
Most Recent Events
Table of Contents
- At a glance
- Trial Overview
- Trial Details
- Trial Centres
- Trial History